



Lead-like Compounds for Screening

The pressures on drug discovery are increasing the demand for novel drug-like molecules for use in early screening. Numerous collections of screening compounds are now commercially available for drug discovery but many are incomplete due to a lack of particular structural features. Peakdale has developed a screening compound collection over the last ten years to provide novel molecules for initial biological screening. Based on elaboration around our own building block collection and using Lipinski's guidelines for "drug-like" properties, we have over 8000 non-exclusive screening compounds readily available from stock. The focus on novelty means that Peakdale's library will enrich any corporate compound collection and allow the exploration of previously unreachable chemical space.

Development

Peakdale applies absorption, distribution, metabolism and excretion (ADME) technology through a collaboration with Cyprotex, a specialist provider of technology and information, to evaluate and optimise the pharmacokinetic properties of potential drugs early in the drug discovery process. Cyprotex uses its Cloe Screen™ high throughput screening technology to evaluate the ADME properties of these compounds. The predictive models developed are used to maximise the drug-like properties of Peakdale's unique screening compounds, in order to provide customers with enhanced compounds that are better characterised, superior starting points for hit discovery and which can thereby lead to significant time-savings in subsequent optimisation.

The Company's parallel synthesis labs support the further development of our collection. Moreover, our scientists are also available for exclusive contracts in the areas of hit discovery, hit-to-lead development and lead optimisation. By applying our medicinal chemistry expertise and adding drug-like features early on, Peakdale adds significant value to customers' drug discovery and lead optimisation programmes.



Supply

We can supply compounds either in vials or plates (96 or 384 wells) as dry films or DMSO solutions. This flexible approach allows us to meet even the most exacting customer requirements.

Further Information

To receive further information regarding Peakdale's screening compounds please contact us;

Telephone +44(0)1298 816700 Fax +44(0)1298 816701 email enquiries@peakdale.co.uk

Applying its innovative chemistry expertise and flexible resources, Peakdale Molecular supports its customers' drug discovery activities through the following products and services;

- **Medicinal Chemistry**
- **Custom Synthesis**
- **Analytical Services**
- **Contract Research**
- **CADD Services**
- **Intermediates Catalogue**
- **Peakexplorer Focused Libraries**
- **Lead-like Compounds for Screening**
- ***In Vitro* ADMET Services**
- **Microwave Synthesis Services**

Founded in 1992, Peakdale Molecular is based in Chapel-en-le-Frith in the UK, where its purpose built facilities house organic research labs, parallel synthesis labs and a kilo scale-up lab, all of which are supported by a fully equipped analytical department.

www.peakdale.com